DIGEST

Summary

Today’s briefing covers significant developments in oncology, including CREATE Medicines' $122 million raise for in vivo CAR-T therapies, advancements in CRISPR-Cas9 technology for cancer treatment, the identification of novel biomarkers for early pancreatic cancer detection, OncoTech's $20 million funding for immunotherapy, and Bristol Myers Squibb's landmark partnership with Hengrui Pharma focusing on early-stage oncology assets. Additionally, we explore the implications of targeting mitochondrial dynamics in cancer treatments.